focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Book has just got very strong, expect a strong mover, imminently
With twitter account now making direct reference to Covid test, they seem to be posturing in anticipation of announcement, something they surely wouldn’t do if the results were not looking encouraging.
https://twitter.com/paraytec1/status/1362376316536819720?s=21
Would be one hell of a bullish reversal if it could go blue form here. It’s track record recently suggests that this isn’t an impossible outcome.
Tom - that can only be your decision, trying to judge this from a technical standpoint is impossible imo. Many have tried and failed as it is in a particularly strong uptrend.
P25- it would be interesting to see AGL subject to a tender offer ‘strategic investment’, like foundation medicine was with Roche before the full takeover. To provide the funds required to target many of the other cancer targets in conjunction with Abbott. This would then also allow AGL to continue to make additional partnerships and keep long term investors in the game.
Pretty confident we will see something from Abbot this year, and others.
I think at a time of consolidation, knowing how quickly the market can flip on this one, now is as good a time as any to consider the next 6 months and our AGL investment:
1) FDA De Novo - 150 days from application on the 25th September is up on Monday the 21st Feb. In the event we don’t receive an interactive question reducing delay (Q submission), we would receive a written question which would be subject to a maximum reply period of 180 days and therefore the latest decision date of August.
https://www.fda.gov/medical-devices/premarket-submissions/de-novo-classification-request
2) Labs - Opening in the Uk as of the end of this month beginning of next and in the US at the end of this quarter.
3) Large Pharma contract ‘shortly’ - likely prior to opening of labs and it has been widely touted in the presentations to date as PD-L1. Further news on the PD-L1 assay as a result.
4) Sample to answer - following significant investment will be subject to an RNS and possibly at 501k Fda submission
5) Ovarian Cancer - subject to a 95% sensitivity when competition is only 25% opening a $2b market with the results due Q2 and an assay in place by year end
6) Nasdaq listing - most likely post FDA and will create a re rating similar to that of MXCT
7) Partnerships - need I say more
With a very busy 6 months of key corporate objectives likely to drive the valuation of the company forward it comes as no surprise that AGL has rerated from a low base (Jupiter).
For me, every drop presents an opportunity. GL
I think at a time of consolidation, knowing how quickly the market can flip on this one, now is as good a time as any to consider the next 6 months and our AGL investment:
1) FDA De Novo - 150 days from application on the 25th September is up on Monday the 21st Feb. In the event we don’t receive an interactive question reducing delay (Q submission), we would receive a written question which would be subject to a maximum reply period of 180 days and therefore the latest decision date of August.
https://www.fda.gov/medical-devices/premarket-submissions/de-novo-classification-request
2) Labs - Opening in the Uk as of the end of this month beginning of next and in the US at the end of this quarter.
3) Large Pharma contract ‘shortly’ - likely prior to opening of labs and it has been widely touted in the presentations to date as PD-L1. Further news on the PD-L1 assay as a result.
4) Sample to answer - following significant investment will be subject to an RNS and possibly at 501k Fda submission
5) Ovarian Cancer - subject to a 95% sensitivity when competition is only 25% opening a $2b market with the results due Q2 and an assay in place by year end
6) Nasdaq listing - most likely post FDA and will create a re rating similar to that of MXCT
7) Partnerships - need I say more
With a very busy 6 months of key corporate objectives likely to drive the valuation of the company forward it comes as no surprise that AGL has rerated from a low base (Jupiter).
For me, every drop presents an opportunity. GL
I believe this project has the third lowest breakeven cost and this isn’t going to public vote?
Yes it will affect short term sentiment but they have to get permission and build the mine first.
Just re read that lol. ‘Translating from Spanish forums’.
I have spent considerable time over Thursday and Friday monitoring the performance of BKY in Madrid and actively on their forums.
I found it strange that over the course of the Wednesday to Friday that the volume represented a churn of over 20% of the share register. Yet their was no real direct read across in volume here. To mention that the share price has also risen 20% in that time.
I found that the increase in activity has been driven by the minutes from Wednesdays meeting by the Spanish nuclear safety council that confirmed that construction authorization was discussed and that it was suggested by what I could understand by translating into from the Spanish forums that a further meeting took place this Friday and that we could expect to hear the outcome no later than Friday the 19th Feb.
Definitely activity that hasn’t been picked up by Uk market or Asx.
20% of the total share register has exchanged hands in 2 days in Spain.
According to the Spanish investor forums the meeting is today. It’s extremely difficult to translate. The volume is extremely high, it is suggest that the meeting will continue until a decision is made.
It’s progress, and completely under the radar in the UK.
https://twitter.com/pullinger_james/status/1360159260999639041?s=21
What they don’t tell you is that the RSI has been overbought since the 4th January, in that time the share price has gone from 47.75 to where it is today.
A chart cannot account for background buying off the book, or key news catalysts that will drive the share price. In this case the PD-L1 assay and large Pharma contract followed by all the other key news to come.
Just look at those companies that had 10 bagged last year and had been overbought for months, it makes no difference to investors who judge a company on its ability to meet its corporate objectives.
Many starting to show colors and their side of the book. Quite simply parsortix is an investment and not to be traded as the rerating still has significant legs over time.
To many key corporate catalysts to ignore between now and August.
Enjoy, investors.
Exactly my thoughts P25, which is why they have no choice but to lift the price to encourage loose stock
Foundation medicine participated in a collaboration in 2015 with Roche via a tender offer for an aggregate tender value of approximately USD 780 million. Roche also invested USD 250 million in Foundation Medicine by acquiring 5 million newly issued shares at USD 50 per share.
3 years later Roche took out the remaining shares for $2.4b, I believe in time we could see a similar deal structure with AGL.
That’s now 700k and counting at 93.1
Seeing about 500k at 93.1 and we know demand was still there at 92.6 for significant amounts. Will be interesting to see if we get any further late reported trades today and tomorrow as part of the demand.
But it’s significant for a number of reasons, not just because it’s good to follow the money at 5 year highs. It goes to show that deeper pockets can see the true potential and are still willing to invest significant sums at this level.
Wow, that order had been filled at 93.1 to the point I was being offered 92.6 for little stock, now they have rebooted and will offer 93.1 for significant amounts of stock again.
Deep institutional pockets or strategic investor?